Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

[Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC)].

Liu YQ, Guo RH, Liu LK, Gao W, Zhu CJ, Wei J, Shu YQ.

Zhonghua Zhong Liu Za Zhi. 2011 Jun;33(6):426-30. Chinese.

PMID:
21875482
2.

Involvement of FoxM1 in non-small cell lung cancer recurrence.

Xu N, Wu SD, Wang H, Wang Q, Bai CX.

Asian Pac J Cancer Prev. 2012;13(9):4739-43.

3.

FoxM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis.

Xu N, Jia D, Chen W, Wang H, Liu F, Ge H, Zhu X, Song Y, Zhang X, Zhang D, Ge D, Bai C.

PLoS One. 2013;8(3):e59412. doi: 10.1371/journal.pone.0059412.

4.

FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.

Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ, Liu WC.

Lung Cancer. 2013 Feb;79(2):173-9. doi: 10.1016/j.lungcan.2012.10.019.

PMID:
23177020
5.

Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer.

Kong FF, Qu ZQ, Yuan HH, Wang JY, Zhao M, Guo YH, Shi J, Gong XD, Zhu YL, Liu F, Zhang WY, Jiang B.

Oncol Rep. 2014 Jun;31(6):2660-8. doi: 10.3892/or.2014.3129.

PMID:
24715097
6.

Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance.

Yang DK, Son CH, Lee SK, Choi PJ, Lee KE, Roh MS.

Hum Pathol. 2009 Apr;40(4):464-70. doi: 10.1016/j.humpath.2008.10.001.

PMID:
19121844
7.

Overexpression of hedgehog pathway molecules and FOXM1 in non-small cell lung carcinomas.

Gialmanidis IP, Bravou V, Amanetopoulou SG, Varakis J, Kourea H, Papadaki H.

Lung Cancer. 2009 Oct;66(1):64-74. doi: 10.1016/j.lungcan.2009.01.007.

PMID:
19200615
8.

FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells.

Xu N, Zhang X, Wang X, Ge HY, Wang XY, Garfield D, Yang P, Song YL, Bai CX.

Acta Pharmacol Sin. 2012 May;33(5):675-81. doi: 10.1038/aps.2011.188.

9.

Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.

Okada K, Fujiwara Y, Takahashi T, Nakamura Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori M, Doki Y.

Ann Surg Oncol. 2013 Mar;20(3):1035-43. doi: 10.1245/s10434-012-2680-0.

PMID:
23054116
10.

Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.

Wang WP, Yan XL, Li WM, Ni YF, Zhao JB, Lu Q, Wang XJ, Sun Y, Chen P, Yan BY, Cui Y, Zhang ZP, Li XF.

Pathol Res Pract. 2015 Dec;211(12):939-47. doi: 10.1016/j.prp.2015.09.010.

PMID:
26554593
11.

Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.

Zhao ZH, Wang SF, Yu L, Wang J, Chang H, Yan WL, Zhang J, Fu K.

Lung Cancer. 2008 Oct;62(1):113-9. doi: 10.1016/j.lungcan.2008.02.014.

PMID:
18550205
12.

High FOXM1 expression was associated with bladder carcinogenesis.

Liu D, Zhang Z, Kong CZ.

Tumour Biol. 2013 Apr;34(2):1131-8. doi: 10.1007/s13277-013-0654-x.

PMID:
23325617
13.

High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients.

Wei LX, Zhou RS, Xu HF, Wang JY, Yuan MH.

Tumour Biol. 2013 Apr;34(2):941-6. doi: 10.1007/s13277-012-0629-3.

PMID:
23264086
14.

Cytoplasmic Forkhead box M1 (FoxM1) in esophageal squamous cell carcinoma significantly correlates with pathological disease stage.

Hui MK, Chan KW, Luk JM, Lee NP, Chung Y, Cheung LC, Srivastava G, Tsao SW, Tang JC, Law S.

World J Surg. 2012 Jan;36(1):90-7. doi: 10.1007/s00268-011-1302-5.

15.

FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer.

Chu XY, Zhu ZM, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB, Mo XB.

Acta Histochem. 2012 Dec;114(8):755-62. doi: 10.1016/j.acthis.2012.01.002.

PMID:
22326401
16.

Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.

Xia JT, Wang H, Liang LJ, Peng BG, Wu ZF, Chen LZ, Xue L, Li Z, Li W.

Pancreas. 2012 May;41(4):629-35. doi: 10.1097/MPA.0b013e31823bcef2.

PMID:
22249132
17.

FOXM1 regulated by ERK pathway mediates TGF-β1-induced EMT in NSCLC.

Kong FF, Zhu YL, Yuan HH, Wang JY, Zhao M, Gong XD, Liu F, Zhang WY, Wang CR, Jiang B.

Oncol Res. 2014;22(1):29-37. doi: 10.3727/096504014X14078436004987.

PMID:
25700356
18.

Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.

Jiang L, Liang X, Liu M, Wang W, Ma J, Guo Q, Han L, Yang C, Nan K.

Oncol Rep. 2014 Nov;32(5):1931-8. doi: 10.3892/or.2014.3432.

PMID:
25175672
19.

NQO1 protein expression predicts poor prognosis of non-small cell lung cancers.

Li Z, Zhang Y, Jin T, Men J, Lin Z, Qi P, Piao Y, Yan G.

BMC Cancer. 2015 Mar 31;15:207. doi: 10.1186/s12885-015-1227-8.

20.

[Correlations of S100A4 and MMP9 expressions to infiltration, metastasis and prognosis of non-small cell lung cancer].

Chen XL, Wang LC, Zhang WG, Chen XY, Sun ZM.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 Jul;28(7):1254-8. Chinese.

Items per page

Supplemental Content

Support Center